https://ujpronline.com/index.php/journal/issue/feedUniversal Journal of Pharmaceutical Research2026-11-15T13:24:11+08:00Prof. Kapil Kumar[email protected]Open Journal Systems<p>Universal Journal of Pharmaceutical research (UJPR) is a peer-reviewed, bi monthly published open access journal aiming to publish original research papers, scientific commentaries, views and review articles, and editorial commentary in the field of the pharmaceutical sciences. The aim of UJPR is to serve as a means for updating the scientific knowledge of the international audience in the pharmaceutical forum and to promote scientific and pharmaceutical research activities related to pharmaceutical education and research, by promoting social contacts among pharma professional of the world.</p>https://ujpronline.com/index.php/journal/article/view/1660Message2026-11-10T21:19:24+08:00Prof. Dr. Barkat Ali Khan[email protected]<p>With immense pleasure and profound responsibility, I present the 5<sup>th</sup> issue of volume 11 2026 of the Universal Journal of Pharmaceutical Research (UJPR). Eleventh volume means 11<sup>th</sup> years that is not merely a number but a testament to sustained research commitment. From its inception, UJPR strives to be more than a collection and repository of data but proudly presents itself to be a bridge between bench and bedside and among the laboratories of global scientific community. UJPR blending the essence of traditional knowledge and cutting-edge current pharmaceutical innovations.</p> <p>Current issue comes at a specific moment for pharmaceutical sciences where the world is witnessing a paradigm shift from conventional dosage forms to novel drug delivery systems and AI-driven drug discovery. The pharmaceutical researchers can feel the shift from isolated research to planetary health. The articles in this issue largely reflect this transition. Our contributors have explored critical areas ranging from natural plant extracts their biological activities, pharmacy practice advances like KAP (Knowledge, Attitude, Practice) of various diseases, antimicrobial resistance and herbal standardization as well as advanced drug delivery systems. We all know that quality research needs quality peer review UJPR has remained steadfast in its commitment to rigorous, double-blind peer review, COPE ethical guidelines, and timely publication without quality fall or even quality compromising.</p> <p>I am surely proud that UJPR has become a voice for researchers from low and middle-income countries, providing a universal compact platform to young scientists, PhD scholars as well as clinical researchers who mostly struggle to find a right place for dissemination their findings and visibility.</p> <p>I warmly invite all researchers, clinicians and industrial pharmacy scientists to continue submitting their high-quality original research and review articles to UJPR. As an editor, I sincerely thank to our reviewers, who are the unsung custodians of quality and scientific integrity.</p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1663IN VITRO ANTIBACTERIAL POTENITAL OF SIX TRADITIONAL PALESTINIAN PLANTS AGAINST STAPHYLOCOCCUS AUREUS AND ESCHERICHIA COLI2026-11-10T22:03:55+08:00Rola Jadallah[email protected]Tahreer Tahaineh[email protected]<p><strong>Aim and objective:</strong> Medicinal plants remain part of Palestinian ethnomedicine, including remedies used for infectious conditions. This work evaluated six commonly used plants for <em>in vitro </em>activity against two representative bacterial pathogens.</p> <p><strong>Methods:</strong> Ethanolic and water extracts of clove (<em>Syzygium aromaticum</em>), cinnamon (<em>Cinnamomum verum</em>), peppermint (<em>Mentha piperita</em>), parsley (<em>Petroselinum crispum</em>), green tea (<em>Camellia sinensis</em>), and silver nailroot (<em>Paronychia argentea</em>) were assessed against <em>Staphylococcus aureus</em> and <em>Escherichia coli</em> using an agar well-diffusion assay.</p> <p><strong>Results:</strong> Ethanolic preparations produced greater antibacterial effects than the corresponding aqueous preparations. Clove showed the strongest overall response, followed by cinnamon and peppermint, whereas green tea and parsley were less active and silver nailroot showed comparatively weak activity. The tested Gram-positive organism was generally more susceptible than the Gram-negative organism.</p> <p><strong>Conclusion:</strong> These <em>in vitro </em>findings identify several Palestinian medicinal plants, particularly clove, as candidates for further antibacterial investigation. Isolation of active constituents, mechanistic studies, and appropriate <em>in vivo</em> safety and efficacy testing are required before therapeutic use can be considered.</p> <h5> <a id="article-1629" href="https://ujpronline.com/index.php/journal/article/view/1629" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/drkc5/r1.jpg" alt="" width="352" height="250" /></a></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 25 July 2026; <strong>Reviewed</strong> 13 September 2026; <strong>Accepted</strong> 6 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. </strong><strong>Ahmad Najib<sub><a href="https://orcid.org/0000-0001-5055-7964" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Universitas Muslim Indonesia, Indonesia, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0002-2683-4746" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Sangeetha Arullappan</strong>, Universiti Tunku Abdul Rahman, Malaysia, <em>[email protected]</em></p> <p><strong><sub><em><a href="https://orcid.org/0000-0003-3669-3542" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></em></sub>Dr. DANIYAN Oluwatoyin Michael</strong>, Obafemi Awolowo University, ILE-IFE, Nigeria,<em> [email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1662PREVALENCE, BIOTYPING, AND ANTIBIOTIC SUSCEPTIBILITY PROFILES OF AEROMONAS SPECIES ISOLATED FROM DIARRHOEAL PATIENTS IN SANA'A CITY, YEMEN 2026-11-10T21:47:12+08:00Sami Sultan Ahmed Abdu[email protected]Sami Sultan Ahmed Abdu[email protected]Sami Mohammed Abdo Hassan[email protected]Hassan Abdulwahab Al-Shamahy[email protected]Ibrahim Mohammed Amed Nahshal[email protected]Ibrahim Ali Al-Arashi[email protected]Amirh Abdullah Sa'aed Aljabri[email protected]Ahmed Mohammed Al-Haddad[email protected]Naif Mohammed Al-Haidary[email protected]<p><strong>Background and Aims:</strong><em> </em>The genus<em> Aeromonas </em>is one of new and increasingly important bacterial genera which have been included as a cause of human gastritis. The aims of the study include determination of the prevalence of <em>Aeromonas </em>species among diarrhoeal patients, as well as biotyping, and studying the antibiotic susceptibility of the isolates.</p> <p><strong>Methods:</strong> Initially patients suffering from diarrhoea were selected from patients who attended the main hospitals in Sana'a and sent to NCPHL for stool culture. A total of 1991 diarrheal stool specimens were collected during the period of two-year period (2023–2024). In order to identify <em>Aeromonas</em> the stool specimens were inoculated into alkaline peptone water, <em>Aeromonas </em>agar and TCBS agar, and then the isolates were identified by the relevant biochemical tests.</p> <p><strong>Results:</strong> Presents data on 1,991 diarrhea patients, predominantly children aged 2 months to 9 years (34.0%). There was a slight male predominance (52.9%). The mean age was 22.4 years, with a range of 2 months to 75 years. The leading bacterial causes were non-Salmonella typhoid serogroups (25.0%), Shigella serogroups (13.0%), and <em>Vibrio cholerae </em>(7.7%). Moderate to low prevalence included enteropathogenic <em>E. coli</em> (5.1%) and <em>Aeromonas</em> (1.9%). Resistance rates for <em>Aeromonas </em>were 100% for PG-penicillin, Ampicillin-sulbactam, Oxacillin, and Ampicillin, with high resistance to nalidixic acid (84.2%).</p> <p><strong>Conclusion</strong>: Diarrheal illness in this study population heavily burdens young children and is primarily driven by non-Salmonella typhoid and Shigella serogroups.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r2.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 26 July 2026; <strong>Reviewed</strong> 3 September 2026; <strong>Accepted</strong> 9 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. A.A. Mgbahurike<sub><a href="https://orcid.org/0000-0002-4355-7250" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, University of Port Harcourt, Nigeria, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0001-5756-5457" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Showkat Ahmad Bhawani</strong>, UNIMAS Sarawak, Malaysia, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0003-0174-8742" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Tamer Elhabibi</strong>, Suez Canal University, Egypt, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1661D-DIMER LEVELS AND THEIR IMPACT ON PREDICTING COVID-19 DISEASE PROGRESSION: A RETROSPECTIVE STUDY AT DIAGNOSTIC LABORATORY, ZIMBABWE 2026-11-10T21:23:48+08:00Lenah Shumba[email protected]Emmanuel Ifeanyi Obeagu[email protected]<p><strong>Background:</strong> Coronavirus disease 2019 (COVID-19) is frequently complicated by coagulation abnormalities, with elevated D-dimer levels consistently associated with severe disease and poor clinical outcomes. Evidence from sub-Saharan Africa, particularly Zimbabwe, remains limited despite the clinical relevance of this biomarker in resource-limited settings.</p> <p><strong>Objective:</strong> To evaluate the impact of D-dimer levels on predicting COVID-19 disease progression among patients tested at a diagnostic laboratory in Zimbabwe between December 2019 and December 2020.</p> <p><strong>Methods:</strong> This retrospective observational study reviewed records of 99 patients with laboratory-confirmed COVID-19 who had documented D-dimer results. Demographic data, D-dimer levels, patient ward location, and indicators of disease severity were analyzed. Severe COVID-19 was defined as admission to a high-dependency unit (HDU) or intensive care unit (ICU). Statistical analyses included descriptive statistics, comparison across age groups and wards, receiver operating characteristic (ROC) curve analysis, and logistic regression to assess the predictive value of D-dimer.</p> <p><strong>Results:</strong> The mean age of patients was 68.04±20.37 years, with a slight female predominance (53.54%). The overall mean D-dimer level was 1.48±2.76 μg/mL. Higher D-dimer concentrations were observed in older age groups and in patients admitted to HDU and ICU. ROC curve analysis demonstrated good discriminatory performance of D-dimer in predicting severe COVID-19. Logistic regression showed a positive association between increasing D-dimer levels and the probability of severe disease.</p> <p><strong>Conclusion:</strong> Elevated D-dimer levels are strongly associated with COVID-19 disease severity and progression in this Zimbabwean cohort. D-dimer is a valuable and accessible prognostic biomarker that can support early risk stratification and clinical decision-making in resource-constrained healthcare settings.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r3.jpg" alt="" width="352" height="251" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 23 July 2026; <strong>Reviewed</strong> 7 September 2026; <strong>Accepted</strong> 5 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Emmanuel O. Olorunsola<sub><a href="https://orcid.org/0000-0002-6041-2563" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Department of Pharmaceutics & Pharmaceutical Technology, University of Uyo, Nigeria, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0002-8264-6328" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Wilman Ismael Carrillo Terán</strong>, Technical University of Ambato Avda, Ecuador, <em>[email protected]</em></p> <p><strong><sub><em><a href="https://orcid.org/0000-0003-3669-3542" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></em></sub>Dr. DANIYAN Oluwatoyin Michael</strong>, Obafemi Awolowo University, ILE-IFE, Nigeria,<em> [email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1664FORMULATION AND EVALUATION OF SODIUM ALGINATE BEADS AND SUSTAINED-RELEASE PELLETS OF RABEPRAZOLE SODIUM2026-11-10T22:10:51+08:00S. Madhankumar[email protected]G. Mariyappan[email protected]J. Karthi[email protected]Prakash Murugan[email protected]<p><strong>Background:</strong> Rabeprazole sodium is a proton pump inhibitor that degrades rapidly in acidic media. Prolonged-release oral forms must therefore limit its exposure to gastric acid while controlling its release in the intestine.</p> <p><strong>Objective:</strong> To develop and evaluate two independent multiparticulate systems of rabeprazole sodium, namely calcium alginate beads and Eudragit RS100-coated sustained-release pellets.</p> <p><strong>Methods: </strong>Calcium alginate beads were generated by ionotropic gelation using a two-factor, three-level factorial arrangement comprising sodium alginate at 2.0–3.0% w/v and calcium chloride at 1.0–2.0% w/v. A separate pellet series was manufactured by powder layering onto sugar spheres and subsequent application of Eudragit RS100 coatings containing triethyl citrate at 0–20% of the polymer mass. Characterization encompassed manufacturing recovery, drug incorporation, particle attributes and UV-derived apparent release. The selected pellet formulation underwent additional release-model fitting, scanning electron microscopy and storage assessment.</p> <p><strong>Results:</strong> Increasing the concentrations of sodium alginate, and calcium chloride increased bead yield (82.4–91.0%), entrapment efficiency (78.6–91.6%) and size, and decreased swelling and drug release at 8 h (from 91.8% to 73.5%). Formulation B5 showed a balanced profile with an entrapment efficiency of 87.6±1.0%. In the pellet series, increasing the triethyl citrate level progressively retarded drug release at 12 h, from 96.8% (F1) to 76.5% (F5). The drug content and 12 h release of F5 changed by less than two percentage points after 6<sup>th</sup> months of accelerated and 12<sup>th</sup> months of long-term storage.</p> <p><strong>Conclusion:</strong> Triethyl citrate concentration was a critical variable governing drug release from Eudragit RS100-coated rabeprazole sodium pellets. Formulation F5 met all predefined quality and release criteria and remained stable during storage, identifying it as a promising sustained-release multiparticulate candidate for further development.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r4u.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 25 July 2026; <strong>Reviewed</strong> 3 September 2026; <strong>Accepted</strong> 8 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Ali Abdullah Al-yahawi<sub><a href="https://orcid.org/0000-0002-1099-7778" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Al-Razi university, Department of Pharmacy, Yemen, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0003-4137-1732" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Eyassu Mathewos</strong>, Department of Nursing, College of Medicine and Health Sciences, Wachamo University, Durame Campus, Durame, Ethiopia, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0001-7823-2790" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Julie Ann S. Ng</strong>, Blk 18 Lot 6 Grandville 3 Subdivision Mansilingan, Bacolod City, Philippines. <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1668SYNTHESIS AND CHARACTERIZATION OF CEFADROXIL-BENZALDEHYDE DERIVED LIGAND, METAL COMPLEXES, AND EVALUATION OF THEIR ANTI-INFLAMMATORY, CYTOTOXIC, AND ANTIMICROBIAL ACTIVITIES2026-11-10T23:00:49+08:00Md. Shahidul Islam[email protected]Samia Syda Nishat[email protected]Md. Rabiul Hossain[email protected]Rukyea Yeasmin Mysha[email protected]Rounak Jahan Israt[email protected]Md. Arif Ahmed[email protected]<p><strong>Background: </strong>The rise of infectious diseases and drug-resistant strains of bacteria and fungi poses a significant challenge, threatening human health and life expectancy. Researchers are actively working to develop novel antimicrobial therapies to counteract these issues.</p> <p><strong>Methods: </strong>In this study, new derivatives were synthesized from (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid (cefadroxil) by reaction with Benzaldehyde. The primary aim was to enhance the antibacterial efficacy of existing antibiotics and develop therapeutically active compounds. The synthesized ligand was characterized through elemental analysis, various physicochemical tests, and multiple spectroscopic techniques, including infrared (IR), <sup>1</sup>H NMR, <sup>13</sup>C NMR, and UV spectroscopy. The ligand underwent solubility and chemical tests and was screened for <em>in vitro</em> antibacterial activity using the disc diffusion method. Anti-inflammatory and antioxidant properties were also evaluated.</p> <p><strong>Results:</strong> Synthesized compound exhibited superior antibacterial properties compared to cefadroxil alone, with significant zones of inhibition and MIC values. Additionally, anti-inflammatory and cytotoxicity tests yielded promising outcomes, indicating potential for future antibiotic applications.</p> <p><strong>Conclusion: </strong>Study concludes that while metal coordination with structural modifications could lead to the discovery of novel lead compounds with enhanced therapeutic potential.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r5u.jpg" alt="" width="352" height="250" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 27 July 2026; <strong>Reviewed</strong> 5 September 2026; <strong>Accepted</strong> 3 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: </strong><strong>Dr. Amany Mohamed Alboghdadly<sub><a href="https://orcid.org/0000-0001-6858-7723" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Ibn Sina National College for Medical Studies in Jeddah, Saudi Arabia, <em>[email protected] </em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0002-3744-2043" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Kian Navaee</strong>, Shahre Daru Pharmaceutical Co., Iran, <em>[email protected]</em></p> <p><strong><a href="https://orcid.org/0000-0002-0734-3036" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a>Dr. Noha El Baghdady</strong>, MTI University, Cairo, Egypt, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1666ANTIBIOTIC RESISTANCE PATTERN OF COAGULASE-NEGATIVE STAPHYLOCOCCI ISOLATED FROM CLINICAL SPECIMENS IN SANA'A CITY, YEMEN2026-11-10T22:35:31+08:00Belques Sharaf Al-Huraibi[email protected]Huda Zaid Al-Shami[email protected]Ola Ahmed Al-Shargabi[email protected]Khaled Abdulkarim Al-Moyed[email protected]Eshrak Adulmalik Al-gunaid[email protected]Sami Sultan Ahmed Abdu[email protected]Sami Mohammed Abdo Hassan[email protected]Hassan Abdulwahab Al-Shamahy[email protected]Ahmed Mohammed Al-Haddad[email protected]<p><strong>Background and aims:</strong> <em>Coagulase-negative Staphylococci</em> (<em>CoNS</em>) are common skin bacteria that can cause serious infections when they enter the body through invasive procedures or wounds. This study aims to evaluate the antibiotic resistance patterns of <em>CoNS</em> isolated from clinical samples in Sana’a city, Yemen, from 2011 to 2021.</p> <p><strong>Subjects and Methods: </strong>Data were collected from 4 laboratories and 3 hospitals using a retrospective cross-sectional design and SPSS software version 25.</p> <p> <strong>Results</strong> This study tested 93 antibiotics for 2729 different clinical samples, and identified the <em>CoNS</em> species and their resistance patterns. Also, found that <em>CoNS</em> were a significant cause of hospital-acquired infections in Sana’a city, with high resistance rates (46.3%). The most common isolated <em>CoNS</em> species were <em>Staphylococcus</em> <em>epidermidis</em>, <em>Staphylococcus</em> <em>saprophyticus</em>, and <em>Staphylococcus</em> <em>hemolyticus</em>. <em>CoNS</em> showed high resistance to β-lactam antibiotics, such as Penicillins (66%) and Cephalosporins (55.9%), and Macrolides; such as Erythromycin (57.1%) and Azithromycin (50.8%). The antibiotic resistance trend increased from 2012 to 2015, with the highest peak increase in 2013 (45.2%), and decreased from 2015 to 2020, but increased again in 2021, possibly due to the COVID-19 pandemic and the overuse of antibiotics.</p> <p><strong>Conclusion: </strong> <em>CoNS</em> are a significant cause of hospital-acquired infections in Sana’a city, with high resistance rates to commonly used antibiotics. The combination of penicillin and β-lactamase inhibitor showed higher resistance than penicillin alone.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r6.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 20 July 2026; <strong>Reviewed</strong> 7 September 2026; <strong>Accepted</strong> 9 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Asia Selman Abdullah<a href="https://orcid.org/0000-0002-7384-0313" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></strong>, <span class="affiliation">Pharmacy institute, University of Basrah, Iraq</span>, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><a href="https://orcid.org/0000-0001-9156-372X" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a>Prof. Cyprian Ogbonna ONYEJI</strong>, Obafemi Awolowo University, Ile-Ife, Nigeria, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0002-1506-1549" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Prof. Gorkem Dulger</strong>, Duzce University, Turkey,<em> [email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1667SEXUAL DIMORPHISM OF SKELETAL CLASS III MALOCCLUSION IN YEMENIS ADULT2026-11-10T22:50:17+08:00Mohammed Abdullah Al-Hababy[email protected]Ramy Abdul Rahman Ishaq[email protected]<p><strong>Aim: </strong>Identification of sexual dimorphism in skeletal Class III malocclusion can help improve clinical diagnosis and orthodontic treatment. There is a continuing dispute as to the extent of sexual dimorphism in skeletal Class III malocclusion. The purpose of this study is to investigate the sexual dimorphism of cephalometric data in Class III malocclusion among Yemeni adults.</p> <p><strong>Methods: </strong>This retrospective cross-sectional study examined 144 lateral cephalographs of Class III malocclusion in Yemeni adults, including 67 men and 77 women, who ranged from 16 to 40 years. The cephalometric x-rays were digitized and traced using OrisCeph RX CE software to measure a total of 48 craniomaxillofacial variables. Descriptive statistics of data were calculated for each gender. To assess sexual dimorphisms across all cephalometric variables, the Mann-Whitney U test was employed.</p> <p><strong>Results: </strong>Most variables indicated that males exhibited greater values than females. Adult Yemeni males with Class III malocclusion had greater values in linear measurements of the cranial base, maxilla, mandible, and facial heights than female patients.</p> <p><strong>Conclusions:</strong> Sexual dimorphism exists in Yemeni adults with skeletal Class III malocclusions. The results are presented to confirm the actual variations in skeletal features between two sexes of Yemeni adults. Sexual dimorphism should be considered in clinical diagnosis, treatment planning, and orthodontic treatment.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r7.jpg" alt="" width="375" height="218" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 27 July 2026; <strong>Reviewed</strong> 6 September 2026; <strong>Accepted</strong> 11 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. DANIYAN Oluwatoyin Michael<sub><em><a href="https://orcid.org/0000-0003-3669-3542" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></em></sub></strong>, Obafemi Awolowo University, ILE-IFE, Nigeria,<em> [email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0003-0400-9080" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Ogbonna B. Onyebuchi</strong>, Nnamdi Azikiwe University, Awka, Nigeria, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0002-7158-2306" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub> Dr. Sheima Nadim Kadhim, </strong>Deparment of Pharmacology and Toxicology, College of pharmacy, University of Basra, Iraq. <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1665IN SILICO EVALUATION OF THE INHIBITORY POWER OF AMIDINOUREA DERIVATIVES FOR PHOSPHOPANTETHEINYL TRANSFERASE IN MYCOBACTERIUM TUBERCULOSIS2026-11-10T22:18:50+08:00Kouakou Jean-Louis Kouakou[email protected]Konan Auriol Kra[email protected]Elvice Akori Esmel[email protected]Mélalie Kéïtaépouse Guego[email protected]Eugene Megnassan[email protected]<p><strong>Background: </strong><em>Tuberculosis</em> (<em>TB</em>) is an infectious, contagious, and fatal disease, according to the 2025 Global Tuberculosis Report of the World Health Organization (WHO). Phosphopantetheinyl transferase (PptT) is an enzyme that acts as a catalyst in the biosynthesis of cellular lipids in <em>Mycobacterium tuberculosis</em>. It is considered potential target for the development of anti-tuberculosis drugs.</p> <p><strong>Methods</strong>: We used molecular docking to establish a quantitative structure-activity relationship (QSAR) model for 25 amidinourea derivatives inhibitors of PptT. The binding free energies, a key physical descriptor, enabled us to elucidate the thermodynamic factors governing the interaction between the enzyme and the inhibitor. This approach, which combines structure-based molecular docking with quantitative modeling, identified specific, critical chemical substituents. This, in turn, led to the development of new derivatives that exhibit potent antitubercular activity. </p> <p><strong>Results: </strong>The resulting QSAR model that accounts for 87% of the variation in biological activity, based on the binding free energies (BFE/PBSA) of the analogues used. Subsequently, an intuitive fragment-replacement approach, based on per-residue interaction energy, which indicates stabilizing interactions, was implemented to identify new analogues. Moreover, 200-ns molecular dynamics simulations have evaluated with satisfaction, the temporal evolution of various properties of the bound inhibitors, such as root mean square deviation (RMSD) from the initial conformation, radius of gyration (rGyr), number of intramolecular hydrogen bonds (intraHB), molecular surface area (molSA), solvent-accessible surface area (SASA), and polar surface area (PSA). The BFE/GBSA of the three best analogs, calculated over the last 50 nanoseconds of the trajectory, align with BFE/PBSA values. Finally, favorable values for the pharmacokinetic descriptors of the best analogues are obtained using the QikProp, pkCSM, and mycoCSM programs.</p> <p><strong>Conclusion: </strong>This study enabled us to identify a new amidinourea analogue AU_1-3-7-9, which is 10 times more active.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/r8.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 22 July 2026; <strong>Reviewed</strong> 3 September 2026; <strong>Accepted</strong> 8 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Prof. Dr. Gorkem Dulger<sub><a href="https://orcid.org/0000-0002-1506-1549" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Duzce University, Turkey,<em> [email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0001-8064-3919" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub> Dr. Sarfaraz Ahmed</strong>, Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand, India, <em>[email protected]</em> </p> <p><strong><sub><a href="https://orcid.org/0000-0002-7158-2306" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Sheima Nadim Kadhim, </strong>Deparment of Pharmacology and Toxicology, College of pharmacy, University of Basra, Iraq. <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1669CLOSING THE GLOBAL PEDIATRIC CANCER SURVIVAL GAP: A PRECISION AND HEALTH-SYSTEMS FRAMEWORK FOR EQUITABLE DIAGNOSIS, ACCESSIBLE TREATMENT, CONTEXT ADAPTED INNOVATION, AND LIFELONG SURVIVORSHIP2026-11-10T23:12:16+08:00Emmanuel Ifeanyi Obeagu[email protected]George Okuma Achar[email protected]Enayi Onaji[email protected]<p>Childhood cancer is increasingly curable, yet profound disparities in survival persist between and within high-resource and low-resource settings. These disparities reflect not only differences in tumour biology but also delayed diagnosis, limited pathology and molecular diagnostics, treatment interruptions, shortages of essential medicines, inadequate transfusion and supportive-care capacity, workforce constraints, financial hardship, and fragmented survivorship services. This narrative review examines a precision and health-systems framework for closing the global pediatric cancer survival gap by integrating equitable diagnosis, accessible treatment, context-adapted innovation, and lifelong survivorship. Precision pediatric oncology is conceptualized beyond genomic medicine to encompass accurate diagnosis, risk stratification, measurable residual disease assessment, individualized treatment intensity, toxicity monitoring, and patient-centred supportive care. Tiered diagnostic pathways, regional referral networks, digital pathology, tele-oncology, task-sharing, essential-medicine strategies, and strengthened laboratory and blood-transfusion systems can expand access while adapting advanced care to local realities. Treatment completion requires attention to transportation, socioeconomic barriers, family education, and financial protection. Equally, survival must extend beyond remission through risk-stratified surveillance for relapse, cardiotoxicity, endocrine dysfunction, infertility, neurocognitive impairment, psychosocial consequences, and secondary malignancies. Sustainable progress requires locally generated evidence, childhood cancer registries, implementation research, equitable research partnerships, and data-driven quality improvement. Closing the survival gap therefore demands coordinated investment across cancer biology, clinical care, health-system infrastructure, financing, workforce development, and survivorship. The goal is not identical care everywhere, but equitable access to effective, safe, context-appropriate, and sustainable pediatric cancer care capable of producing durable survival and healthy adulthood.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw1.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 27 July 2026; <strong>Reviewed</strong> 8 September 2026; <strong>Accepted</strong> 5 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Gehan Fawzy Abdel Raoof Kandeel<sub><a href="https://orcid.org/0000-0002-8021-5460" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Pharmacognosy Department, National Research Centre, Dokki, 12622, Giza, Egypt, <em>[email protected]</em> </p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0002-4370-8864" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Prof. Syamsudin Abdillah</strong>, Pancasila University, Indonesia, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0002-1506-1549" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Prof. Gorkem Dulger</strong>, Duzce University, Turkey,<em> [email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1670SOCIODEMOGRAPHIC AND LIFESTYLE PREDICTORS OF GLYCEMIC CONTROL AMONG PEOPLE WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW2026-11-10T23:22:27+08:00Seerat Shahzad[email protected]Asma Ashraf[email protected]Sitwat Zia[email protected]Fatima Azhar[email protected]Maryam Nadeem[email protected]Muhammad Aeqan Azhar[email protected]Fukaiha Kamran[email protected]Hafiz Muhammad Bilal[email protected]Abdul Rehman Abid[email protected]Naqyia Batool Naqvi[email protected]<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) has become a major health problem worldwide, and many of those that develop T2DM are still struggling to maintain optimal glycemic control. The sociodemograpic and lifestyle factors can play a significant role on diabetes management and treatment outcomes.</p> <p><strong>Objective: </strong>To explore the relationship between sociodemographic factors and lifestyle-related factors and glycemic control in adults with type 2 diabetes mellitus (T2DM).</p> <p><strong>Methodology: </strong>A systematic review was undertaken following the PRISMA guidelines which were registered with PROSPERO (CRD420251163620). PubMed, Scopus, Web of Science, Science Direct, ProQuest, Google Scholar and DOAJ were systematically searched to find the literature. Studies from January 2014 – September 2026 in English and relevant languages were conducted. Studies for review were limited to those involving adults with T2DM that measured sociodemographic/lifestyle factors that affect glycemic control. The MMAT 2018 tool was used to evaluate the quality of the studies.</p> <p><strong>Results: </strong>A total of 23 studies were found. Lower education level, low income, rural living, older age, obesity, physical inactivity, unhealthy diet, smoking, and poor adherence to medication was a common factor with poor glycemic control. Less diabetes self-management and less good glycemic control were also correlated with other psychosocial factors including low self-efficacy, inadequate social support, and depression.</p> <p><strong>Conclusion: </strong>There are various social, behavioral and psychological factors that have an impact on glycemic control in T2DM. Health education, Lifestyle change, adherence to medication, and psychosocial support can help to provide patient centered interventions that help to control glycemic targets and minimize diabetes complications.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw2.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 21 July 2026; <strong>Reviewed</strong> 9 September 2026; <strong>Accepted</strong> 6 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Iman Muhammad Higazy<em><a href="https://orcid.org/0000-0002-4200-0418" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></em></strong>, National Research Center, Egypt, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0001-7910-6841" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Prof. Amani S. Awaad</strong>, Prince Sattam Bin Abdulaziz University, Al-Kharj. KSA., <em>[email protected]</em></p> <p><strong><a href="https://orcid.org/0000-0001-9156-372X" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a>Prof. Cyprian Ogbonna ONYEJI</strong>, Obafemi Awolowo University, Ile-Ife, Nigeria, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1671PHARMACOVIGILANCE AND REGULATORY ACTION IN EAST AFRICA WITH A FOCUS ON TANZANIA: A SCOPING REVIEW2026-11-11T00:57:25+08:00Lambert Philipo Barugahale[email protected]Sechelela Vincent Lemanya[email protected]Kennedy John Ndetico[email protected]Lewis Mwombeki[email protected]<p><strong>Background:</strong> Pharmacovigilance (PV) detects, assesses and prevents adverse drug reactions (ADRs) and other medicine-related problems. East African countries have built national PV systems, but underreporting and the weak visibility of links between safety information and regulatory decisions persist.</p> <p><strong>Objectives:</strong> To map evidence on PV systems and regulatory action in East Africa with emphasis on Tanzania; to quantify key PV outcomes among health professionals; to identify factors associated with ADR reporting; and to describe how safety information is translated into regulatory action.</p> <p><strong>Methods:</strong> Rapid scoping review following the Arksey and O’Malley framework, Joanna Briggs Institute guidance and PRISMA-ScR reporting, with a conditional quantitative synthesis. Targeted searches of web-indexed biomedical literature, repositories and regulatory and media sources were run in October 2026.</p> <p><strong>Results:</strong> Twenty-five sources were charted: 17 research sources (Tanzania, Uganda, Kenya, Ethiopia, Rwanda and two multi-country studies) and eight regulatory, programme and media reports. In 2017/18, spontaneous reporting was 4.1 reports per million inhabitants in mainland Tanzania, 6.7 in Ethiopia and 35.0 in Kenya, and no more than 1% of facilities submitted reports. Nine surveys of health professionals (n=3,091) gave a pooled ADR-reporting proportion of 30.3% (95% CI 19.1–44.4%; I²=97.9%; 95% prediction interval 4.3–81.0%).</p> <p><strong>Conclusions:</strong> PV structures have advanced and reporting can be raised sharply by training and stimulated reporting, but low and uneven reporting, training gaps and limited visibility of locally triggered regulatory action constrain medicine safety.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw3.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 25 July 2026; <strong>Reviewed</strong> 3 September 2026; <strong>Accepted</strong> 8 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Jennifer Audu-Peter<a href="https://orcid.org/0000-0002-3234-0347" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></strong>, University of Jos, Nigeria, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><a href="https://orcid.org/0000-0002-0734-3036" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a>Dr. Noha El Baghdady</strong>, MTI University, Cairo, Egypt, <em>[email protected]</em></p> <p><span class="name"><strong><sub><a href="https://orcid.org/0009-0006-2249-3477" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Mayada M. El-Azab, </strong></span> <span class="affiliation"> Phytochemistry Unit, Department of Medicinal and Aromatic Plants, Desert Research Center, Cairo, Egypt. <em>[email protected]</em></span></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1672ECHOES OF A PANDEMIC: HOW HIV CONTINUES TO BESIEGE THE GLOBE2026-11-11T01:04:34+08:00Jucimary Vieira dos Santos[email protected]<p>The progression from initial HIV contraction to a formal AIDS classification can span two decades-a prolonged incubation window identified when the disease was first classified before evolving into a major worldwide health crisis. Patient populations exhibit significant variance in how the infection manifests clinically. Historically, this protracted, symptom-free phase triggered widespread psychological trauma, burdening both marginalized communities and healthcare systems. In the early years of the outbreak, the foremost priority for individuals and advocacy groups was securing cost-effective medical treatment and mental health resources amid profound social ostracization. Today, despite disparities in international distribution, dozens of antiretroviral therapies have been authorized, with many more in developmental pipelines. Even so, an absolute cure or preventative vaccine is still unavailable, and secondary opportunistic mycoses still result in thousands of annual fatalities. Deeper insights into the immunopathogenic mechanisms of the virus are vital for optimizing specialized testing and therapeutic management. Accordingly, this study examines how demographic variables, community literacy, and cultural attitudes intersect regarding HIV/AIDS, alongside an assessment of changing healthcare models and targeted epidemiological strategies.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw4.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 25 July 2026; <strong>Reviewed</strong> 3 September 2026; <strong>Accepted</strong> 8 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Marwa A. A. Fayed<sub><a href="https://orcid.org/0000-0001-5609-7436" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>,<strong> </strong>University of Sadat City, Egypt, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0001-7823-2790" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Julie Ann S. Ng</strong>, Blk 18 Lot 6 Grandville 3 Subdivision Mansilingan, Bacolod City, Philippines. <em>[email protected]</em></p> <p><strong><a href="https://orcid.org/0000-0001-5055-7964" target="_blank" rel="noopener"><sub><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></sub></a>Dr. Essam Mohamed Eissa</strong>, Beni-Suef – 32 Tahrir St, Egypt, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1674PRESCRIBING PATTERNS AND RATIONAL USE OF MEDICINES IN EAST AFRICA: A SYSTEMATIC REVIEW2026-11-11T01:16:29+08:00Lambert Philipo Barugahale[email protected]Kennedy John Ndetico[email protected]<p><strong>Background: </strong>Irrational prescribing including polypharmacy, over-use of antibiotics and injections, and low adherence to essential medicines lists (EML) remains a persistent problem across low- and middle-income countries, with important implications for Antimicrobial Resistance (AMR), treatment cost, and patient safety in general.</p> <p><strong>Objective: </strong>To synthesize published evidence on prescribing patterns and rational medicine use in East African countries using WHO/INRUD core prescribing indicators, and to compare practices across countries and healthcare settings under WHO supervision.</p> <p><strong>Methods: </strong>This review follows a PRISMA 2020-guided protocol. Eligible studies were cross-sectional, retrospective, or prospective observational studies reporting one or more WHO/INRUD prescribing indicators in Tanzania, Kenya, Uganda, Rwanda, Burundi, South Sudan, or Ethiopia. This manuscript reports a narrative synthesis based on ten primary studies and one regional multi-country synthesis identified through structured searches; formal multi-database screening and quality appraisal using the JBI checklist are outlined as next steps.</p> <p><strong>Results: </strong>Across identified studies, the average number of medicines per encounter ranged from 1.8 to 3.2 (WHO optimal: 1.6-1.8), generic-name prescribing ranged from approximately 51% to 98% (optimal: 100%), antibiotic-encounter prevalence ranged from 23% to 84%, injection-encounter prevalence ranged from 7% to 14%, and EML conformity ranged from approximately 96% to 100%. No eligible studies were located for Rwanda, Burundi, or South Sudan in this search.</p> <p><strong>Conclusion: </strong>Published data indicate persistent deviation from WHO optimal prescribing values in East Africa, particularly for polypharmacy and antibiotic over-prescribing, alongside comparatively strong performance on EML conformity. Findings support continued antimicrobial stewardship and prescriber-education interventions, and highlight an evidence gap for several East African countries.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw6.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 28 July 2026; <strong>Reviewed</strong> 5 September 2026; <strong>Accepted</strong> 9 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. </strong><strong>Nuray Arı<sub><a href="https://orcid.org/0000-0002-9259-7427" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Ankara University, Turkiye,<em> [email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><span class="gI"><strong><em><span data-hovercard-id="[email protected]" data-hovercard-owner-id="107"><sub><a href="https://orcid.org/0000-0002-6706-4995" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></span></em>Dr. Vanina Doris Edo’o</strong></span><span class="gI">, University of Yaounde I, Yaounde, Cameroun, </span><em><span class="gI"><span data-hovercard-id="[email protected]" data-hovercard-owner-id="107">[email protected]</span></span></em></p> <p><strong><sub><a href="https://orcid.org/0000-0003-0174-8742" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Tamer Elhabibi</strong>, Suez Canal University, Egypt, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1673PERIOPERATIVE ANTICOAGULATION MANAGEMENT: A HEMATOLOGIST–CARDIOLOGIST PERSPECTIVE ON RISK STRATIFICATION AND THERAPEUTIC DRUG MONITORING2026-11-11T01:10:37+08:00Emmanuel Ifeanyi Obeagu[email protected]Olga Goryacheva[email protected]<p>Direct oral anticoagulants (DOACs) are widely used for thromboprophylaxis in atrial fibrillation and venous thromboembolism. Their marketing emphasizes predictable pharmacokinetics and no need for routine monitoring. However, the perioperative period exposes critical limitations of this paradigm, especially in high‑risk populations excluded from landmark trials. This narrative review integrates hematology and cardiology perspectives. We critically examined real‑world evidence on perioperative DOAC management, focusing on patients with extreme body weight, renal or hepatic impairment, active malignancy, thrombocytopenia, bariatric surgery, and drug–drug interactions. Guideline recommendations and commercial influences were analyzed. Routine therapeutic drug monitoring (TDM) is unnecessary for low‑risk elective procedures in standard patients. However, selective TDM is essential in high‑risk populations where DOAC pharmacokinetics are unpredictable. We identified specific indications for TDM (extreme body weight, CrCl<50 mL/min, Child‑Pugh B cirrhosis, bariatric surgery, interacting drugs) and provided practical algorithms for elective, urgent and emergency surgery. Low‑Molecular‑Weight heparin (LMWH) is preferred when DOAC pharmacokinetics are unpredictable, including malabsorption syndromes, severe thrombocytopenia, and advanced liver disease. Marketing influences have perpetuated the “no monitoring” dogma despite accumulating evidence of harm in vulnerable subgroups. A one‑size‑fits‑all approach to perioperative anticoagulation is unsafe in complex patients. Selective TDM improves safety in high‑risk scenarios. LMWH remains a preferred alternative when DOAC pharmacokinetics are unpredictable. Clinicians should recognise marketing influences and adopt evidence‑based, individualised strategies.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw5.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 25 July 2026; <strong>Reviewed</strong> 11 September 2026; <strong>Accepted</strong> 9 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Essam Mohamed Eissa<sub><a href="https://orcid.org/0000-0001-8428-6373" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong><strong>, </strong>Beni-Suef University, Egypt, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><em><a href="https://orcid.org/0000-0002-3888-5110" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></em></sub>Dr. Taiwo O Elufioye</strong>, University of Ibadan, Nigeria, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0001-5756-5457" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Showkat Ahmad Bhawani</strong>, UNIMAS Sarawak, Malaysia, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1676CENTRAL MEDICAL STORES AND ESSENTIAL MEDICINE AVAILABILITY IN SUB-SAHARAN AFRICA: A SYSTEMATIC REVIEW WITH A FOCUS ON TANZANIA’S MEDICAL STORES 2026-11-11T01:40:51+08:00Kennedy John Ndetico[email protected]Lambert Philipo Barugahale[email protected]Rebecca Alex Mkama[email protected]Veronica Joseph Mbunda[email protected]Julieth Malifimbo[email protected]Edward Mwakatuma[email protected]Emmanuel Shabani Mandilindi[email protected]Edwin Charles Wambwe[email protected]<p><strong>Background:</strong> Central medical stores are the principal route by which many low- and middle-income countries seek to ensure that essential medicines reach public hospitals, yet the evidence on how they perform and how this affects patient care remains fragmented.</p> <p><strong>Objectives:</strong> To examine how the performance of central medical stores relates to the availability of essential medicines and patient outcomes in tertiary and referral hospitals across sub-Saharan Africa, with Tanzania as the focus and Kenya, Uganda, and Ghana as comparators.</p> <p><strong>Methods:</strong> This systematic review was conducted in line with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance. Open-access literature was searched, and only sources carrying a digital object identifier were kept.</p> <p><strong>Results:</strong> In Tanzania, the availability of essential health commodities increased by 12.6% (95% confidence interval 9.6 to 15.6) following Global Fund-supported reforms, and tracer medicine availability in a pilot region went from 69% to 94% once a prime vendor system was introduced. Central store order fulfillment stood at 58.6% in a Tanzanian baseline survey and between 51% and 60% at a Kenyan referral hospital. In Uganda, 84% of 128 facilities reported at least one stock-out during the previous six months, while introduction of an online ordering portal coincided with an increase in order fill rate from 72.6% to 81.4% across 54 hospitals. In Ghana, the availability of 65 essential medicines at a regional store declined from 100% to 52% after framework agreements were adopted (preprint). None of the studies used a randomized or matched comparator, and none recorded hospital mortality together with central store performance.</p> <p><strong>Conclusion:</strong> Reforms coincided with improved availability in Tanzania and Uganda but with reduced availability in Ghana, indicating that design and implementation both count. Evidence connecting central store performance to patient outcomes in tertiary hospitals is limited and indirect.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw7.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 25 July 2026; <strong>Reviewed</strong> 4 September 2026; <strong>Accepted</strong> 8 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Tamer Elhabibi<sub><a href="https://orcid.org/0000-0003-0174-8742" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, Suez Canal University, Egypt, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><sub><a href="https://orcid.org/0000-0002-2683-4746" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Sangeetha Arullappan</strong>, Universiti Tunku Abdul Rahman, Malaysia, <em>[email protected]</em></p> <p><strong><sub><a href="https://orcid.org/0000-0002-8751-990X" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Dr. Sally A. El-Zahaby</strong>, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Salman International University, Egypt, <em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Researchhttps://ujpronline.com/index.php/journal/article/view/1675WAR AND BLOOD TRANSFUSION CRISES: ADDRESSING BLOOD SHORTAGES, COLD-CHAIN DISRUPTIONS AND TRANSFUSION RISKS THROUGH CONFLICT-RESILIENT BLOOD SYSTEMS2026-11-11T01:35:35+08:00Emmanuel Ifeanyi Obeagu[email protected]Oripha Chimwara[email protected]Okwudili B. Nwankwo[email protected]<p>Armed conflict results in a complicated situation for blood transfusion services by halting blood collection, decreasing donor availability, harming healthcare infrastructure, disrupting cold-chain processes, and raising the demand for vital transfusions. These problems affect trauma victims, women dealing with obstetric hemorrhage, children suffering from severe anemia, and those requiring ongoing transfusion support. This narrative review examines the impact of conflict on blood supply, the quality of components, transfusion safety, and continuous care. It analyzes shortages caused by conflicts, failures in refrigeration, delays in transportation, disruptions in compatibility testing, emergency blood transfusion releases, and lack of hemovigilance. Focus is on methods to improve resilience in blood services, including decentralized collection and distribution, strategic inventory management, solar-powered refrigeration, authorized alternative transport, digital traceability, and patient blood management. The evaluation also includes fair distribution, safeguarding the healthcare workforce, regulatory supervision, and humanitarian partnership. Advanced technologies like drones and renewable energy systems can enhance operational continuity but need validation, ongoing funding, and context-specific assessment. Future studies ought to evaluate cold-chain efficiency, compare logistics, enhance hemovigilance, and analyze cost-effectiveness and equitable access. Ultimately, successful blood transfusion services must integrate reliable infrastructure, trained personnel, evidence-based clinical protocols, structured supply networks, and continuous quality evaluation to reduce preventable transfusion-related harm and uphold life-saving assistance before, during, and after military conflicts.</p> <h5> <img src="https://ujpronline.com/public/site/images/drkc5/rw8uuu.jpg" alt="" /></h5> <p><strong>Peer Review History: </strong></p> <p><strong>Received</strong> 22 July 2026; <strong>Reviewed</strong> 5 September 2026; <strong>Accepted</strong> 8 October; <strong>Available online</strong> 15 November 2026</p> <p><strong>Academic Editor: Dr. Muhammad Zahid Iqbal<sub><a href="https://orcid.org/0000-0001-7486-9479" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub></strong>, AIMST University, Malaysia, <em>[email protected]</em></p> <p><strong>Reviewers:</strong></p> <p><strong><a href="https://orcid.org/0000-0001-7032-528X" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a>Dr. Sabah Hussien El-Ghaiesh</strong>, Tanta University, Egypt, <em>[email protected]</em></p> <p><strong><span class="name"><sub><a href="https://orcid.org/0000-0002-2693-7307" target="_blank" rel="noopener"><img src="https://ujpronline.com/public/site/images/editor/orcid22.jpg" /></a></sub>Rusmir Baljic, </span></strong> <span class="affiliation"> Clinic for infectious diseases, Clinical center University of Sarajevo, Bosnia and Herzegovina. </span><em>[email protected]</em></p>2026-11-15T00:00:00+08:00Copyright (c) 2026 Universal Journal of Pharmaceutical Research